Broad-Spectrum Antiviral Agents: A Crucial Pandemic Tool

References

• Center for Health Security. The characteristics of pandemic pathogens. cited Mar 4, 2019. Available from: http://www.centerforhealthsecurity.org/our-work/pubs_archive/pubs-pdfs/2018/180510-pandemic-pathogens-report.pdf.
   Google Scholar
• Whitley RJ, Gnann JJ. Acyclovir: a decade later. N Engl J Med. 1992;327:782–789.
   PubMed Web of Science ®Google Scholar
• Goldner T, Hewlett G, Ettischer N, et al. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011;85:10884–10893.
   PubMed Web of Science ®Google Scholar
• Poveda E, Briz V, Soriano V. Enfuviritide, the first inhibitor to treat HIV infection. AIDS Rev. 2005;7:139–147.
   PubMed Web of Science ®Google Scholar
• Clark DN, Hu J. Hepatitis B virus reverse transcriptase-target of current antiviral therapy and future drug development. Antiviral Res. 2015;123:132–137.
   PubMed Web of Science ®Google Scholar
• Miller RH, Robinson WS. Common evolutionary origin of hepatitis B virus and retroviruses. PNAS. 1986;83:2531–2535.
   PubMed Web of Science ®Google Scholar
• MacArthur RD, Novak RM. Maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis. 2008;47:236–241.
   PubMed Web of Science ®Google Scholar
• AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed March 4, 2019.
   Google Scholar
• Child K, Davis C, Cannon MD. PS-181-Unacceptably low SVR rates in African patients with unusual HCV sub-genotypes: implications for global elimination. J of Hepatology. 2019;70:e81.
   Web of Science ®Google Scholar
• Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet. 2000;355:827–835.
   PubMed Web of Science ®Google Scholar
• Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018;379:913–923.
   PubMed Web of Science ®Google Scholar
• Geary RS, Henry SP, Grillone LR. Fomivirsen: clinical pharmacology and potential drug interactions. Clin Pharmacokinet. 2002;41:255–260.
   PubMed Web of Science ®Google Scholar
• Shadman KA, Wald ER. A review of palivizumab and emerging therapies for respiratory syncytial virus. Expert Opin Biol Ther. 2011;11:1455–1467.
   PubMed Web of Science ®Google Scholar
• Bettiker RL, Koren DE, Jacobson JM. Ibalizumab. Curr Opin HIV AIDS. 2018;13:354–358.
   PubMed Web of Science ®Google Scholar
• Grosenbach DW, Honeychurch K, Rose EA, et al. Oral tecovirimat for the treatment of smallpox. N Engl J Med. 2018;379:44–53.
   PubMed Web of Science ®Google Scholar
• Rosenke K, Feldmann H, Westover JB, et al. Use of favipiravir to treat Lassa virus infection in macaques. Emerg Infect Dis. 2018;24(9). Accessed 2019 Mar 5. Available from: https://wwwnc.cdc.gov/eid/article/24/9/18-0233_article
   Web of Science ®Google Scholar
• Sissoko D, Laouenan C, Folkesson E, et al. JIKI study group. Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med. 2016;13(6):e1002066.
   PubMedGoogle Scholar
• Raabe VN, Kann G, Ribner BS, et al. Favipiravir and ribavirin treatment of epidemiologically linked cases of Lassa fever. Clin Infect Dis. 2017;65:855–859.
   PubMed Web of Science ®Google Scholar
• Safrin S, Cherrington JM, Jaffe HS. Clinical uses of cidofovir. Rev Med Virol. 1997;7:145–156.
   PubMed Web of Science ®Google Scholar
• Camargo JF, Morris MI, Abbo LM, et al. The use of brincidofovir for the treatment of mixed dsDNA viral infection. J Clin Virol. 2016;83:1–4.
   PubMed Web of Science ®Google Scholar
• Dunning J, Kennedy SB, Antierens A, et al. Experimental treatment of Ebola virus disease with brincidofovir. PLoS One. 2016;11:e0162199.
   PubMed Web of Science ®Google Scholar
• Aoki FY. Antiviral drugs for influenza and other respiratory virus infections. In: Mandell, Douglas, and Bennett’s principles and practice of infectious disease, 8th ed. 2015; Philadelphia: Elselvier. 531.
   Google Scholar
• Agostini ML, Andres EL, Sims AC, et al. Coronavirus suspecitibily to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio. 2018;9:e00221–18.
   PubMed Web of Science ®Google Scholar
• Toth K, Ying B, Tollefson AE, et al. Valganciclovir inhibits human adenovirus replication and pathology in permissive immunosuppressed female and male Syrian hamsters. Virus. 2015;7:1409–1421.
   Google Scholar
• Gish RG, Lau JY, Brooks L, et al. Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Hepatology. 1996;23:1–7.
   PubMed Web of Science ®Google Scholar
• Andrei G, Gillemot S, Topalis D, et al. The anti-human immunodeficiency virus drug tenofovir, a reverse transcriptase inhibitor targets the herpes simplex virus DNA polymerase. J Infect Dis. 2018;2177:7790–7801.
   Google Scholar
• Crumpacker CS. Mechanism of action of foscarnet against viral polymerases. Am J Med. 1992;92:3S–7S.
   PubMed Web of Science ®Google Scholar
• De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev. 2003;16:569–596.
   PubMed Web of Science ®Google Scholar
• Kern ER. In vitro activity of potential anti-poxvirus agents. Antiviral Res. 2003;57:35–40.
   PubMed Web of Science ®Google Scholar
• McMahon MA, Jilek BL, Brennan TP, et al. The anti-hepatitis B drug entecavir inhibits HIV-1 replication and can select HIV-1 variants resistant to antiretroviral drugs. N Engl J Med. 2007;356:2614–2621.
   PubMed Web of Science ®Google Scholar
• Chu CM, Cheng CV, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59:252–256.
   PubMed Web of Science ®Google Scholar
• Aoki FY. Antivirals against herpes viruses. In: Mandell, Douglas and Bennett’s principles and practice of infectious disease, 8th ed. 2015; Philadelphia: Elselvier. 531.
   Google Scholar
• Rossignol JF. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res. 2014;110:94–103.
   PubMed Web of Science ®Google Scholar
• Dowall SD, Bewley K, Watson RJ, et al. Antiviral screening of multiple compounds against Ebola virus. Viruses. 2016;277.
   Web of Science ®Google Scholar
• Zhu Z, Dimitrov AS, Bossart KN, et al. Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. J Virol. 2006;80:891–899.
   PubMedGoogle Scholar
• The PREVAIL II Writing Group. A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med. 2016;375:1448–1456.
   PubMed Web of Science ®Google Scholar